Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone for Duchenne Muscular Dystrophy (DMD)
For more information on the agreement and the clinical development of Vamorolone please clink link below:
We use cookies to ensure that we give you the best experience on our website. You agree to the use of cookies by closing this banner, by scrolling this page, by clicking a link or by continuing to browse otherwise.OkCookies Policy
